Contribution of serotonin to cardiac remodeling associated with hypertensive diastolic ventricular dysfunction in rats

Journal of Hypertension

Volumn 33, Issue 11, 2015, Pages 2310-2321

  Ayme Dietrich, Estelle ^a   Marzak, Halim ^a   Lawson, Roland ^a   Mokni, Walid ^a   Wendling, Olivia ^b   Combe, Roy ^b   Becker, Julien ^b   Fertak, Lahcen El ^b   Champy, Marie France ^b   Matz, Rachel ^c   Andriantsitohaina, Ramaroson ^d   Doly, Stephane ^e   Boutourlinsky, Katia ^e   Maroteaux, Luc ^e   Monassier, Laurent ^a,b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b INSTITUT CLINIQUE DE LA SOURIS   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d UNIVERSITÉ D'ANGERS   (France)

^e INSTITUT DU FER À MOULIN   (France)

Author keywords

5 HT2B Receptors; Fibrosis; Hypertension; Hypertrophy; Serotonin; Spontaneously hypertensive rats

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NICARDIPINE; RS 127445; SEROTONIN 2 ANTAGONIST; SEROTONIN 2B RECEPTOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; 2-AMINO-4-(4-FLUORONAPHTH-1-YL)-6-ISOPROPYLPYRIMIDINE; PYRIMIDINE DERIVATIVE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; ANIMAL; BLOOD PRESSURE; DRUG EFFECTS; ECHOCARDIOGRAPHY; GENETICS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD PRESSURE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART VENTRICLES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, KNOCKOUT; NATRIURETIC PEPTIDE, BRAIN; PYRIMIDINES; RATS; RATS, INBRED SHR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN; SEROTONIN ANTAGONISTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84943189651     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000695     Document Type: Article

References (26)

1. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The Euro Heart Failure survey programme: A survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24:442-463.
2. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, et al. Differences between patients with a preserved and a depressed left ventricular function: A report from the Euro Heart Failure Survey. Eur Heart J 2004; 25:1214-1220.
3. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359:2456-2467.
4. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781.
5. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998; 280:574-577.
6. Colombo F, Noel J, Mayers P, Mercier I, Calderone A. beta-Adrenergic stimulation of rat cardiac fibroblasts promotes protein synthesis via the activation of phosphatidylinositol 3-kinase. J Mol Cell Cardiol 2001; 33:1091-1106.
7. Nebigil CG, Hickel P, Messaddeq N, Vonesch JL, Douchet MP, Monassier L, et al. Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function. Circulation 2001; 103:2973-2979.
8. Nebigil CG, Jaffre F, Messaddeq N, Hickel P, Monassier L, Launay JM, et al. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation 2003; 107:3223-3229.
9. Jaffre F, Callebert J, Sarre A, Etienne N, Nebigil CG, Launay JM, et al. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation 2004; 110:969-974.
10. Monassier L, Laplante MA, Jaffre F, Bousquet P, Maroteaux L, de Champlain J. Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice. Hypertension 2008; 52:301-307.
11. Liang YJ, Lai LP, Wang BW, Juang SJ, Chang CM, Leu JG, et al. Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-kappaB in cardiomyocytes. Cardiovasc Res 2006; 72:303-312.
12. Marzak H, Ayme-Dietrich E, Lawson R, Mokni W, Combe R, Becker J, et al. Old spontaneously hypertensive rats gather together typical features of human chronic left-ventricular dysfunction with preserved ejection fraction. J Hypertens 2014; 32:1307-1316.
13. Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, et al. RS-127445: A selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharmacol 1999; 127:1075-1082.
14. Gonzàlez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, et al. Transcriptome fingerprints distinguish hallucinogenic and non-hallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 2003; 23:8836-8843.
15. Nebigil CG, Choi D-S, Dierich A, et al. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA 2000; 97:9508-9513.
16. Matz RL, de Sotomayor MA, Schott C, Stoclet JC, Andriantsitohaina R. Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids. Br J Pharmacol 2000; 131:303-311.
17. Martinez MC, Muller B, Stoclet JC, Andriantsitohaina R. Alteration by lipopolysaccharide of the relationship between intracellular calcium levels and contraction in rat mesenteric artery. Br J Pharmacol 1996; 118:1218-1222.
18. Cingolani OH, Yang XP, Cavasin MA, Carretero OA. Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension 2003; 41:249-254.
19. Dupont S, Maizel J, Mentaverri R, Chillon JM, Six I, Giummelly P, et al. The onset of left ventricular diastolic dysfunction in SHR rats is not related to hypertrophy or hypertension. Am J Physiol Heart Circ Physiol 2012; 302:H1524-H1532.
20. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nature Med 2002; 8:1129-1135.
21. Jaffre F, Bonnin P, Callebert J, Debbabi H, Setola V, Doly S, et al. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res 2009; 104:113-123.
22. Yabanoglu S, Akkiki M, Seguelas MH, Mialet-Perez J, Parini A, Pizzinat N. Platelet derived serotonin drives the activation of rat cardiac fibro-blasts by 5-HT2A receptors. J Mol Cell Cardiol 2009; 46:518-525.
23. Brattelid T, Qvigstad E, Birkeland JA, Swift F, Bekkevold SV, Krobert KA, et al. Serotonin responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle. J Mol Cell Cardiol 2007; 43:767-779.
24. Brattelid T, Tveit K, Birkeland JA, Sjaastad I, Qvigstad E, Krobert KA, et al. Expression of mRNA encoding G protein-coupled receptors involved in congestive heart failure: A quantitative RT-PCR study and the question of normalisation. Basic Res Cardiol 2007; 102:198-208.
25. Watts SW, Fink GD. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats. Am J Physiol 1999; 276 (3 Pt 2):H944-H952.
26. Manivet P, Mouillet-Richard S, Callebert J, Nebigil CG, Maroteaux L, Hosoda S, et al. PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor. J Biol Chem 2000; 275:9324-9331.